Increasing the Therapeutic Ratio of Stereotactic Ablative Radiotherapy by Individualized Isotoxic Dose Prescription

Journal of the National Cancer Institute

Volumn 108, Issue 2, 2016, Pages

  Zindler, Jaap D ^a   Thomas, Charles R ^b   Hahn, Stephen M ^c   Hoffmann, Aswin L ^a,d,e   Troost, Esther G C ^a,d,e   Lambin, Philippe ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^e UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CONTROL; HUMAN; MORBIDITY; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; RADIOTHERAPY; REVIEW; STEREOTACTIC BODY RADIATION THERAPY; THERAPEUTIC INDEX; TUMOR VOLUME; ADVERSE EFFECTS; ANIMAL; BRAIN NEOPLASMS; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; NEOPLASMS; ORGANS AT RISK; PATHOLOGY; PRESCRIPTION; PROCEDURES; RADIATION DOSE FRACTIONATION; RADIATION INJURIES; RADIATION RESPONSE; RADIOSURGERY; RADIOTHERAPY PLANNING SYSTEM; SECONDARY; STANDARDS; TREATMENT OUTCOME;

ANIMALS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; DOSE FRACTIONATION; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; NEOPLASMS; ORGANS AT RISK; PRESCRIPTIONS; RADIATION INJURIES; RADIOSURGERY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84962532790     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv305     Document Type: Review

References (53)

1. Beasley M, Driver D, Dobbs HJ. Complications of radiotherapy: improving the therapeutic index. Cancer Imaging. 2005;5:78-84.
2. van Elmpt W, Öllers M, Velders M, et al. Transition from a simple to a more advanced dose calculation algorithm for radiotherapy of non-small cell lung cancer (NSCLC): implications for clinical implementation in an individualized dose-escalation protocol. Radiother Oncol. 2008;88(3):326-334.
3. De Ruysscher D, van Baardwijk A, Steevens J, et al. Individualised isotoxic accelerated radiotherapy and chemotherapy are associated with improved long-term survival of patients with stage III NSCLC: a prospective population- based study. Radiother Oncol. 2012;102(2):228-233.
4. Bentzen SM, Constine LS, Deasy JO, et al. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S3-S9.
5. Jackson A, Marks LB, Bentzen SM, et al. The lessons of QUANTEC: recommendations for reporting and gathering data on dose-volume dependencies of treatment outcome. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S155-S160.
6. Marks LB, Yorke ED, Jackson A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S10-S19.
7. Kirkpatrick JP, Kelsey CR, Palta M, et al. Stereotactic body radiotherapy: a critical review for nonradiation oncologists. Cancer. 2014;120(7):942-954.
8. Senan S, Palma DA, Lagerwaard FJ. Stereotactic ablative radiotherapy for stage I NSCLC: Recent advances and controversies. J Thorac Dis. 2011;3(3):189-196.
9. de Vin T, Engels B, Gevaert T, Storme G, De Ridder M. Stereotactic radiotherapy for oligometastatic cancer: a prognostic model for survival. Ann Oncol. 2014;25(2):467-471.
10. Bentzen SM, Dörr W, Gahbauer R, et al. Bioeffect modeling and equieffective dose concepts in radiation oncology - terminology, quantities and units. Radiother Oncol. 2012;105(2):266-268.
11. Leksell L. The stereotaxic method and radiosurgery of the brain. Acta Chir Scand.1951;102(4):316-319.
12. Palma DA, Salama JK, Lo SS, et al. The oligometastatic state-separating truth from wishful thinking. Nat Rev Clin Oncol. 2014;11(9):549-557.
13. Tree AC, Khoo VS, Eeles RA, et al. Stereotactic body radiotherapy for oligometastases. Lancet Oncol. 2013;14(1):e28-e37.
14. Zindler JD, Rodrigues G, Haasbeek CJ, et al. The clinical utility of prognostic scoring systems in patients with brain metastases treated with radiosurgery. Radiother Oncol. 2013;106(3):370-374.
15. Kocher M, Soffietti R, Abacioglu U, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol. 2011;29(2):134-141.
16. Palma D, Visser O, Lagerwaard FJ, Belderbos J, Slotman BJ, Senan S. Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis. J Clin Oncol. 2010;28(35):5153-5159.
17. Senthi S, Lagerwaard FJ, Haasbeek CJ, Slotman BJ, Senan S. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-smallcell lung cancer: a retrospective analysis. Lancet Oncol. 2012;13(8):802-809.
18. Crabtree T, Puri V, Timmerman R, et al. Treatment of stage I lung cancer in high-risk and inoperable patients: comparison of prospective clinical trials using stereotactic body radiotherapy (RTOG 0236), sublobar resection (ACOSOG Z4032), and radiofrequency ablation (ACOSOG Z4033). J Thorac Cardiovasc Surg. 2013;145(3):692-699.
19. Hurkmans CW, Cuijpers JP, Lagerwaard FJ, et al. Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study. Radiat Oncol. 2009;12:1.
20. Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366(10):925-931.
21. Stamell EF, Wolchok JD, Gnjatic S, Lee NY, Brownell I. The abscopal effect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phys. 2013;85(2):293-295.
22. Rödel F, Frey B, Multhoff G, Gaipl U. Contribution of the immune system to bystander and nontargeted effects of ionizing radiation. Cancer Lett. 2013:S0304-S3835.
23. Zegers CM, Rekers NH, Quaden DH, et al. Radiotherapy combined with the immunocytokine L19-IL2 provides long-lasting antitumor effects. Clin Cancer Res. 2015;21(5):1151-1160.
24. Lo SS, Loblaw A, Chang EL, et al. Emerging applications of stereotactic body radiotherapy. Future Oncol. 2014;10(7):1299-1310.
25. Palma DA, Verbakel WF, Otto K, Senan S. New developments in arc radiation therapy: a review. Cancer Treat Rev. 2010;36(5):393-399.
26. Salama JK, Milano MT. Radical Irradiation of Extracranial Oligometastases. J Clin Oncol. 2014:32(26):2902-2912.
27. Sheehan JP, Yen CP, Lee CC, Loeffler JS. Cranial Stereotactic Radiosurgery: Current Status of the Initial Paradigm Shifter. J Clin Oncol. 2014:32(26):2836-2846.
28. Seung SK, Larson DA, Galvin JM, et al. American College of Radiology (ACR) and American Society for Radiation Oncology (ASTRO) Practice Guideline for the Performance of Stereotactic Radiosurgery (SRS). Am J Clin Oncol. 2013;36(3):310-315.
29. Ong CL, Palma D, Verbakel WF, Slotman BJ, Senan S. Treatment of large stage I-II lung tumors using stereotactic body radiotherapy (SBRT): planning considerations and early toxicity. Radiother Oncol. 2010;97(3):431-436.
30. Corradetti MN, Haas AR, Rengan R. Central-airway necrosis after stereotactic body-radiation therapy. N Engl J Med. 2012;366(24):2327-2329.
31. Barney BM, Olivier KR, Macdonald OK, Fong de los Santos LE, Miller RC, Haddock MG. Clinical outcomes and dosimetric considerations using stereotactic body radiotherapy for abdominopelvic tumors. Am J Clin Oncol. 2012;35(6):537-542.
32. Sahgal A, Weinberg V, Ma L, et al. Probabilities of radiation myelopathy specific to stereotactic body radiation therapy to guide safe practice. Int J Radiat Oncol Biol Phys. 2013;85(2):341-347.
33. Sahgal A, Whyne CM, Ma L, et al. Vertebral compression fracture after stereotactic body radiotherapy for spinal metastases. Lancet Oncol. 2013;14(8):e310-e320.
34. Wu AJ, Williams E, Modh A, et al. Dosimetric predictors of esophageal toxicity after stereotactic body radiotherapy for central lung tumors. Radiother Oncol. 2014;112(2):267-271.
35. Lo SS, Sahgal A, Chang EL, et al. Serious complications associated with stereotactic ablative radiotherapy and strategies to mitigate the risk. Clin Oncol (R Coll Radiol). 2013;25(6):378-387.
36. Timmerman RD. An overview of hypofractionation and introduction to this issue of seminars in radiation oncology. Semin Radiat Oncol. 2008;18(4):215-222.
37. ICRU Report 83: Prescribing, recording and reporting intensity-modulated photon-beam therapy (IMRT). J ICRU. 2010;10(1):10.1093.
38. Kirkpatrick JP, Wang Z, Sampson JH, et al. Defining the optimal planning target volume in image-guided stereotactic radiosurgery of brain metastases: results of a randomized trial. Int J Radiat Oncol Biol Phys. 2015;91(1):100-108.
39. Wiggenraad R, Verbeek-de Kanter A, Kal HB, Taphoorn M, Visser T, Struikmans H. Dose-effect relation in stereotactic radiotherapy for brain metastases: A systematic review. Radiother Oncol. 2011;98(3):292-297.
40. Brouwer CL, Steenbakkers RJ, Gort E, et al. Differences in delineation guidelines for head and neck cancer result in inconsistent reported dose and corresponding NTCP. Radiother Oncol. 2014;111(1):148-152.
41. Park C, Papiez L, Zhang S, Story M, Timmerman RD. Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys. 2008;70(3):847-852.
42. Daly ME, Luxton G, Choi CY, et al. Normal tissue complication probability estimation by the Lyman-Kutcher-Burman method does not accurately predict spinal cord tolerance to stereotactic radiosurgery. Int J Radiat Oncol Biol Phys. 2012;82(5):2025-2032.
43. Cheung YK, Chappell R. Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics. 2000;56(4):1177-1182.
44. Pijls-Johannesma M, van Mastrigt G, Hahn SM, et al. A systematic methodology review of phase I radiation dose escalation trials. Radiother Oncol. 2010;95(2):135-141.
45. Hoffmann AL, Troost EG, Huizenga H, Kaanders JH, Bussink J. individualized dose prescription for hypofractionation in advanced non-smallcell lung cancer radiotherapy: an in silico trial. Int J Radiat Oncol Biol Phys. 2012;83(5):1596-1602.
46. Baardwijk A, Wanders S, Boersma L, et al. Mature results of an individualized radiation dose prescription study based on normal tissue constraints in stages I to III non-small-cell lung cancer. J Clin Oncol. 2010;28(8):1380-1386.
47. Baardwijk A, Bosmans G, Bentzen SM, et al: Radiation dose prescription for non-small-cell lung cancer according to normal tissue dose constraints: An in silico clinical trial. Int J Radiat Oncol Biol Phys. 2008;71(4):1103-1110.
48. Reymen B, van Baardwijk A, Wanders R, et al. Long-term survival of stage T4N0-1 and single station IIIA-N2 NSCLC patients treated with definitive chemo-radiotherapy using individualised isotoxic accelerated radiotherapy (INDAR). Radiother Oncol. 2014;110(3):482-487.
49. Oberije C, Nalbantov G, Dekker A, et al. A prospective study comparing the predictions of doctors versus models for treatment outcome of lung cancer patients: A step toward individualized care and shared decision making. Radiother Oncol. 2014;112(1):37-43.
50. Lambin P, van Stiphout RG, Starmans MH, et al. Predicting outcomes in radiation oncologymultifactorial decision support systems. Nat Rev Clin Oncol. 2013;10(1):27-40.
51. Williams TM, Maier A. Role of stereotactic body radiation therapy and proton/ carbon nuclei therapies. Cancer J. 2013;19(3):272-281.
52. Roelofs E, Engelsman M, Rasch C, et al. Results of a multicentric in silico clinical trial (ROCOCO): comparing radiotherapy with photons and protons for non-small cell lung cancer. J Thorac Oncol. 2012;7(1):165-176.
53. Joiner M, van der Kogel A. Basic Clinical Radiobiology. 4th edition. London, United Kingdom: Hodder Arnold; 2009.